CDKN2B and cancer: Accordingly, the INK4b/ARF/INK4a locus is deleted or downregulated in about 40% of human cancers, mainly related to the tumor suppressive function of CDKN2A and CDKN2B [65]; conversely, ANRIL itself shows a pro-oncogenic activity [63].